The Asia Pacific single-cell analysis market is projected to reach USD 1,375 million by 2025 from USD 550 million in 2020, at a CAGR of 20.1% during the forecast period. Growth in this market is mainly driven by factors such as the increasing R&D in the pharmaceutical and biotechnology industries for complex diseases, growing focus on personalized medicine, growth in stem cell research, and the rising prevalence of cancer. However, the high cost of single-cell analysis products is a major factor hampering the growth of the Asia Pacific single-cell analysis market.
The major players in this market are Becton, Dickinson and Company (US), Danaher Corporation (US), Merck Millipore (US), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific, Inc. (US), General Electric Company (US), Promega Corporation (US), Illumina, Inc. (US), Bio-Rad Laboratories (US), Fluidigm Corporation (US), Agilent Technologies, Inc. (US), Tecan Group Ltd. (Switzerland), Sartorius AG (Germany), Luminex Corporation (US), Takara Bio (Japan), 10x Genomics (US), Fluxion Biosciences (US), Menarini Silicon Biosystems, Inc. (Italy), bioMérieux SA (France), Oxford Nanopore Technologies (UK), Cytek Biosciences (US), Corning Incorporated (US), Apogee Flow Systems Ltd. (UK), NanoCellect Biomedical (US), and On-chip Biotechnologies Co., Ltd. (Japan).
To know about the assumptions considered for the study download the pdf brochure
In 2019, Merck Millipore held the leading position in the Asia Pacific single-cell analysis market. The company offers lab materials, services, and technologies for the research, development, and production of pharmaceutical and biotechnology drug therapies. The company’s Life Science segment offers single-cell analysis products. Merck adopts organic growth strategies such as product launches and expansions to increase its dominance in this market. The company also focuses on enhancing its presence in the high-growth Asian region to increase its market share and revenue. In the last three years, the company has opened life science centers in China, India, and Singapore.
Danaher Corporation accounted for the second-largest share of the Asia Pacific single-cell analysis market in 2019. The company offers a broad range of products in the single-cell analysis market, including flow cytometers, cell counters, mass spectrometers, reagents, and kits. The company adopts the strategies of product launches and acquisitions. Over the years, Danaher has acquired several players operating in the single-cell analysis market, such as Beckmann Coulter and Molecular Devices.
QIAGEN N.V. is a provider of sample and assay technologies for applied testing, pharmaceutical research, and molecular diagnostics and serves over 500,000 customers across the globe. The company adopts the strategies of product launches and collaborations in order to offer innovative solutions and sustain its leading position in the market. For instance, in November 2019, the company introduced the QIAseq Multimodal Panels, which aid in consolidated workflows to simultaneously detect DNA variants, RNA fusions, and gene expression levels from a single sample. Such developments have helped the company enhance its visibility in the market.
Asia Pacific Single-cell Analysis Market by Cell Type (Human, Animal, Microbial), Product (Reagent, Assays, Instruments), Technique (Flow Cytometry, NGS, PCR), Application (Cancer, Stemcell, IVF), End User (Academic, Research Labs) - Forecast to 2025
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE